Magnesium/lithium preparations for neuroprotection and neurotrophic benefits

Abstract

Neuroprotective preparations (formulations) employing the synergistic, neurotrophic benefits of nutritional lithium With bioavailable magnesium (FIG. 1 ). The biological synergism of lithium and magnesium is further enhanced with a proprietary base of synergistic, neurotrophic nutrients. A highly-effective, trans-mucosal, delivery system is included to provide exceptional bioavailability of a palatable, convenient intra-oral preparation, which saturates the vascular tissue in the oral cavity for efficient absorption. Additionally, methods of use are described, allowing for effective, safe, and convenient use of this novel, neuroprotective, antioxidant, anti-inflammatory preparation for humans and animals.

1 - 14 . (canceled) 
     
     
         15 . A method of down-regulating an inflammatory response in a subject, comprising administering to a subject an amount effective to promote an anti-inflammatory response of a composition comprising elemental lithium in an amount of 0.30-30 milligrams and elemental magnesium in an amount of 50-800 milligrams. 
     
     
         16 . The method of  claim 15 , wherein said composition further comprises 2-15 mg zinc glycinate. 
     
     
         17 . The method of  claim 16 , wherein said composition further comprises 50-200 mcg selenium glycinate. 
     
     
         18 . The method of  claim 15 , wherein said elemental lithium further comprises a salt of one or more of orotic acid, aspartic acid, succinic acid, gluconic acid, lysinic acid, malic acid, tauric acid, and gluconic acid to form a lithium chelate. 
     
     
         19 . The method of  claim 15 , wherein said elemental magnesium further comprises a salt of one or more of orotic acid, aspartic acid, succinic acid, gluconic acid, lysinic acid, malic acid, tauric acid, and gluconic acid to form a magnesium chelate. 
     
     
         20 . The method of claim  8 , wherein said composition further comprises an orally administratable form that comprises a partially orally-absorbable preparation. 
     
     
         21 . A method of down-regulating an inflammatory response in a subject, comprising administering to a subject an amount effective to promote an anti-inflammatory response of a composition comprising elemental lithium in an amount of 0.30-20 milligrams and elemental magnesium in an amount of 50-400 milligrams. 
     
     
         22 . The method of  claim 21 , wherein said composition further comprises 2-15 mg zinc glycinate. 
     
     
         23 . The method of  claim 22 , wherein said composition further comprises 50-200 mcg selenium glycinate. 
     
     
         24 . The method of  claim 21 , wherein said elemental lithium further comprises a salt of one or more of orotic acid, aspartic acid, succinic acid, gluconic acid, lysinic acid, malic acid, tauric acid, and gluconic acid to form a lithium chelate. 
     
     
         25 . The method of  claim 21 , wherein said elemental magnesium further comprises a salt of one or more of orotic acid, aspartic acid, succinic acid, gluconic acid, lysinic acid, malic acid, tauric acid, and gluconic acid to form a magnesium chelate. 
     
     
         26 . The method of  claim 21 , wherein said composition is in an orally administratable form further comprising a partially orally-absorbable preparation. 
     
     
         27 . A method of down-regulating an inflammatory response in a subject, comprising administering to a subject an amount effective to promote an anti-inflammatory response of a composition comprising elemental lithium in an amount of 3-10 milligrams and elemental magnesium in an amount of 50-400 milligrams. 
     
     
         28 . The method of  claim 27 , wherein said composition further comprises 2-15 mg zinc glycinate. 
     
     
         29 . The method of  claim 28 , wherein said composition further comprises: 50-200 mcg selenium glycinate. 
     
     
         30 . The method of  claim 27 , wherein said elemental lithium further comprises with a salt of one or more of orotic acid, aspartic acid, succinic acid, gluconic acid, lysinic acid, malic acid, tauric acid, and gluconic acid to form a lithium chelate. 
     
     
         31 . The method of  claim 27 , wherein said elemental magnesium further comprises with a salt of one or more of orotic acid, aspartic acid, succinic acid, gluconic acid, lysinic acid, malic acid, tauric acid, and gluconic acid to form a magnesium chelate. 
     
     
         32 . The method of  claim 27 , wherein said composition further comprises an orally administratable form further comprising a partially orally-absorbable preparation.